Disease Domain | Count |
---|---|
Endocrinology and Metabolic Disease | 6 |
Neoplasms | 2 |
Nervous System Diseases | 1 |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 3 |
Chemical drugs | 2 |
Hormone | 1 |
Target |
Mechanism SSTR2 agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism ACTH receptor antagonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism PTH1R agonists |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePreclinical |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date02 Jan 2024 |
Sponsor / Collaborator |
Start Date12 Oct 2023 |
Sponsor / Collaborator |
Start Date03 Jul 2023 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
Paltusotine ( SSTR2 ) | Acromegaly More | Phase 3 |
Atumelnant ( ACTH receptor ) | Congenital Adrenal Hyperplasia Due to 21 Hydroxylase Deficiency More | Phase 2 |
Parathyroid Hormone Receptor Type-1 Antagonist(Crinetics Pharmaceuticals) ( PTH1R ) | Hypercalcemia More | Preclinical |
PTH Antagonist(Crinetics) ( PTH1R ) | Hyperthyroidism More | Preclinical |
CRN02481 ( SSTR5 ) | Hyperinsulinism More | Preclinical |